TY - JOUR
T1 - The therapeutic potential of naringenin
T2 - A review of clinical trials
AU - Salehi, Bahare
AU - Fokou, Patrick Valere Tsouh
AU - Sharifi-Rad, Mehdi
AU - Zucca, Paolo
AU - Pezzani, Raffaele
AU - Martins, Natália
AU - Sharifi-Rad, Javad
N1 - Publisher Copyright:
© 2019 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2019/3/1
Y1 - 2019/3/1
N2 - Naringenin is a flavonoid belonging to flavanones subclass. It is widely distributed in several Citrus fruits, bergamot, tomatoes and other fruits, being also found in its glycosides form (mainly naringin). Several biological activities have been ascribed to this phytochemical, among them antioxidant, antitumor, antiviral, antibacterial, anti-inflammatory, antiadipogenic and cardioprotective effects. Nonetheless, most of the data reported have been obtained from in vitro or in vivo studies. Although some clinical studies have also been performed, the main focus is on naringenin bioavailability and cardioprotective action. In addition, these studies were done in compromised patients (i.e., hypercholesterolemic and overweight), with a dosage ranging between 600 and 800 µM/day, whereas the effect on healthy volunteers is still debatable. In fact, naringenin ability to improve endothelial function has been well-established. Indeed, the currently available data are very promising, but further research on pharmacokinetic and pharmacodynamic aspects is encouraged to improve both available production and delivery methods and to achieve feasible naringenin-based clinical formulations.
AB - Naringenin is a flavonoid belonging to flavanones subclass. It is widely distributed in several Citrus fruits, bergamot, tomatoes and other fruits, being also found in its glycosides form (mainly naringin). Several biological activities have been ascribed to this phytochemical, among them antioxidant, antitumor, antiviral, antibacterial, anti-inflammatory, antiadipogenic and cardioprotective effects. Nonetheless, most of the data reported have been obtained from in vitro or in vivo studies. Although some clinical studies have also been performed, the main focus is on naringenin bioavailability and cardioprotective action. In addition, these studies were done in compromised patients (i.e., hypercholesterolemic and overweight), with a dosage ranging between 600 and 800 µM/day, whereas the effect on healthy volunteers is still debatable. In fact, naringenin ability to improve endothelial function has been well-established. Indeed, the currently available data are very promising, but further research on pharmacokinetic and pharmacodynamic aspects is encouraged to improve both available production and delivery methods and to achieve feasible naringenin-based clinical formulations.
KW - Cardiovascular diseases
KW - Chemopreventive
KW - Citrus
KW - Flavanones
KW - Flavonoids
KW - Nutraceutics
KW - Phytochemicals
UR - https://www.scopus.com/pages/publications/85060568285
U2 - 10.3390/ph12010011
DO - 10.3390/ph12010011
M3 - Artículo de revisión
AN - SCOPUS:85060568285
SN - 1424-8247
VL - 12
JO - Pharmaceuticals
JF - Pharmaceuticals
IS - 1
M1 - 11
ER -